GT307

Autologous tumor-infiltrating lymphocytes (GT307) · Grit Biotechnology

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for GT307, covering 2026-04-14 to 2026-04-16. Get the full timeline:

Most recent: Clinical Trial Update: A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the Treatment of Metastatic and Recurrent Advanced Solid Tumors [NA]

See pricing